source
- NewLimit secures $435M funding, valuation tops $3B, aims for human trials in 2027NewLimit, a Bay Area anti-aging biotech, announced a financing round that raised $435 million, valuing the company at more than $3 billion. The round is among the largest private biotech financing…
- Contraline secures $92.5M Series B to fund Phase 3 trial of male contraceptive gelContraline, a startup developing a male contraceptive, announced it has closed a Series B financing round worth $92.5 million. The capital will be used to advance its candidate, referred to as NES…